UK markets closed

Silence Therapeutics plc (SLN.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
560.00-2.00 (-0.36%)
At close: 4:35PM GMT
Full screen
Previous close562.00
Open565.26
Bid544.00 x 0
Ask548.00 x 0
Day's range532.00 - 567.26
52-week range330.00 - 646.50
Volume57,930
Avg. volume191,218
Market cap466.515M
Beta (5Y monthly)1.30
PE ratio (TTM)N/A
EPS (TTM)-28.10
Earnings date14 Sep 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est277.00
  • Globe Newswire

    Silence Therapeutics Appoints Craig Tooman as Chief Financial Officer

    Silence Therapeutics Appoints Craig Tooman as Chief Financial Officer   6 January 2021 LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced the appointment of Craig Tooman as the Company’s Chief Financial Officer (CFO) and member of the Executive Leadership Team, effective immediately. Mr. Tooman has a successful career in the biopharmaceutical industry spanning more than 30 years, including 15 years of experience as a public company CFO. Most recently, he was CFO and COO at Vyome Therapeutics, and prior to this was CFO and then CEO of Aratana Therapeutics where he successfully negotiated a merger with Elanco. Before Aratana, Mr. Tooman was the CFO of Enzon Pharmaceuticals until its acquisition by Sigma Tau, and prior to that led the $1.1 billion M&A initiative and integration of ILEX Oncology and Genzyme Corporation. He also held key positions at Pharmacia and Upjohn. Mr. Tooman currently serves on the Supervisory Board and Audit Committee of CureVac, which accomplished a highly successful IPO on Nasdaq in August of 2020. Mr. Tooman has a BA in Economics from Kalamazoo College and an MBA from the University of Chicago. Mark Rothera, President and CEO of Silence Therapeutics, commented: “Craig brings a deep understanding of financial strategy, U.S. capital markets and business development to Silence. We are delighted to have him join Silence’s Executive Leadership Team. His appointment comes at a time of significant opportunity and growth, highlighted by the advancement of our two wholly owned product candidates into the clinic and three anticipated clinical data readouts this year. His business and financial expertise will be instrumental in helping us build our U.S. footprint and positioning Silence as a leading global RNAi business.” Craig Tooman, incoming CFO of Silence Therapeutics, commented: “Silence is a fast-growing company with ground-breaking technology that stands out in the RNAi space. It is exciting to join at this stage of the Company’s journey, following a number of recent successful partnerships and transformational deals. I look forward to working with the team to continue the momentum.” Enquiries: Silence Therapeutics plcGem Hopkins, Head of IR and Corporate Communicationsir@silence-therapeutics.com  Tel:  +1 (646) 637-3208  Investec Bank plc (Nominated Adviser and Broker) Daniel Adams/Gary Clarence    Tel:  +44 (0) 20 7597 5970European IRConsilium Strategic CommunicationsMary-Jane Elliott/ Angela Gray / Chris Welshsilencetherapeutics@consilium-comms.com  Tel: +44 (0) 20 3709 5700U.S. IRWestwicke PartnersPeter Vozzopeter.vozzo@westwicke.com   Tel: +1 (443) 213-0505 About Silence TherapeuticsSilence Therapeutics is developing a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence’s proprietary technology can be used to engineer short interfering ribonucleic acids (siRNAs) that bind specifically to and silence, through the RNAi pathway, almost any gene in the human genome to which siRNA can be delivered. Silence’s wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of Lipoprotein(a) and SLN124 to address beta-thalassemia and myelodysplastic syndrome. Silence is also developing SLN500, a C3 targeting program in partnership with Mallinckrodt Pharmaceuticals to reduce the expression of the C3 protein for the treatment of complement pathway-mediated diseases.  Silence maintains ongoing research and collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/ Forward-Looking StatementsCertain statements made in this announcement are forward-looking statements, including with respect to the Company’s clinical and commercial prospects. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions.  Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

  • Globe Newswire

    Silence Therapeutics Appoints Michael H. Davidson, MD, to Board of Directors

    Silence Therapeutics Appoints Michael H. Davidson, MD, to Board of Directors Leading expert in lipidology to support Silence as it advances new approach to treating cardiovascular disease with lead product candidate SLN360 6 January 2021 LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that Michael H. Davidson, MD, has joined the Silence Board as a Non-Executive Director.   Iain Ross, Chairman of the Board of Silence Therapeutics commented: “Dr. Davidson’s experience as both a researcher and clinician, published author and leading expert on lipidology make him a perfect addition to our Board as we continue to strengthen our proprietary pipeline, including our wholly owned lead product candidate, SLN360, for cardiovascular disease. His unique perspectives that come from having conducted more than 1,000 clinical trials during his career will provide us with valuable insights as we look to rapidly advance our programs through clinical development.” Dr. Davidson is currently a Professor of Medicine and Director of the Lipid Clinic at the University of Chicago and serves as Chief Executive Officer of New Amsterdam Pharma.  During his more than 30-year career, Dr. Davidson has published more than 350 medical journal articles and authored three books on lipidology. His research background encompasses both pharmaceutical and nutritional clinical trials, including extensive research on statins, novel lipid-lowering drugs, and omega-3 fatty acids.  Dr. Davidson founded the Chicago Center for Clinical Research, which became the largest investigator site in the United States and was acquired by Pharmaceutical Product Development in 1996. Additionally, he founded Omthera Pharmaceuticals in 2008, which was acquired by AstraZeneca in 2013 for $440M, and most recently, he was Founding CEO/CSO of Corvidia Therapeutics, which was acquired by Novo Nordisk for up to $2.1B in 2020. As a board-certified physician in internal medicine, cardiology, and clinical lipidology, Dr. Davidson was President (2010-2011) of the National Lipid Association, named as one of The Best Doctors in America for the past 15 years and “Father of the Year” by the American Diabetes Association in 2010. He also serves on the Board of Directors of NASDAQ-listed Caladrius BioScience. Mark Rothera, President and CEO of Silence Therapeutics commented: “It is a pleasure to welcome Dr. Davidson to the Board. As we advance SLN360 through the clinic this year, we look forward to benefiting from his deep expertise in cardiovascular drug development. Further, his proven track record of growing successful biotech companies will be of value to us as we continue to advance our innovative GalNAc siRNA platform globally.” Michael H. Davidson, MD, incoming Silence Therapeutics Board member commented: “Silence has shown great promise with its competitive technology in RNAi, a space which has continued to grab the attention of large pharma. As a lipidology expert, I am impressed with the data obtained so far on SLN360 and I look forward to working with the rest of the Board and the Silence team as the company progresses SLN360 in the clinic this year and advances its GalNAc siRNA platform more broadly.” Director Disclosures The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies: Michael H. Davidson, MD Full name and age: Michael Harvey Davidson (aged 64). Current Directorships or Partnerships:NewAmsterdam Pharma B.V.Inositec AGSonogene LLCCaladrius Biosciences, IncPHP Precision Med Previous Directorships or Partnerships in the last 5 years:Corvidia Therapeutics IncCerenis Therapeutics  No further information in connection with his appointment is required to be disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies. Enquiries: Silence Therapeutics plcGem Hopkins, Head of IR and Corporate Communicationsir@silence-therapeutics.com  Tel:  +1 (646) 637-3208  Investec Bank plc (Nominated Adviser and Broker) Daniel Adams/Gary Clarence    Tel:  +44 (0) 20 7597 5970European IRConsilium Strategic CommunicationsMary-Jane Elliott/ Angela Gray / Chris Welshsilencetherapeutics@consilium-comms.com  Tel: +44 (0) 20 3709 5700U.S. IRWestwicke PartnersPeter Vozzopeter.vozzo@westwicke.com   Tel: +1 (443) 213-0505 About Silence TherapeuticsSilence Therapeutics is developing a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence’s proprietary technology can be used to engineer short interfering ribonucleic acids (siRNAs) that bind specifically to and silence, through the RNAi pathway, almost any gene in the human genome to which siRNA can be delivered. Silence’s wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of Lipoprotein(a) and SLN124 to address beta-thalassemia and myelodysplastic syndrome. Silence is also developing SLN500, a C3 targeting program, in partnership with Mallinckrodt Pharmaceuticals to reduce the expression of the C3 protein for the treatment of complement pathway-mediated diseases.  Silence maintains ongoing research and collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/ Forward-Looking StatementsCertain statements made in this announcement are forward-looking statements, including with respect to the Company’s clinical and commercial prospects. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions.  Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

  • Globe Newswire

    Silence Therapeutics to Participate in January Virtual U.S. Investor Conferences

    Silence Therapeutics to Participate in January Virtual U.S. Investor Conferences 5 January 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that Company management will participate in a fireside chat at two upcoming investor conferences, details of which can be found below: H.C. Wainwright BioConnect 2021 Conference Date: January 11, 2021Time: 6:00 a.m. EST (13:00 GMT) ICR Conference 2021 Date: Thursday, January 14, 2021Time: 8:30- 9:10 a.m. EST (13:30 - 14:10 GMT) Live webcasts of the Company's presentations can be accessed via the Investors section of the Company's website at www.silence-therapeucs.com. An archived replay of the webcasts will be available for 60 days on the Company's website following the conference. Enquiries: Silence Therapeutics plcGem Hopkins, Head of IR and Corporate Communicationsir@silence-therapeutics.com  Tel:  +1 (646) 637-3208  Investec Bank plc (Nominated Adviser and Broker) Daniel Adams/Gary Clarence    Tel:  +44 (0) 20 7597 5970European IRConsilium Strategic CommunicationsMary-Jane Elliott/ Angela Gray / Chris Welshsilencetherapeutics@consilium-comms.com  Tel: +44 (0) 20 3709 5700U.S. IRWestwickePeter Vozzopeter.vozzo@westwicke.com   Tel: +1 (443) 213-0505 About Silence TherapeuticsSilence Therapeutics is developing a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence’s proprietary technology can be used to engineer short interfering ribonucleic acids (siRNAs) that bind specifically to and silence, through the RNAi pathway, almost any gene in the human genome to which siRNA can be delivered. Silence’s wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of Lipoprotein(a) and SLN124 to address beta-thalassemia and myelodysplastic syndrome. Silence is also developing SLN500, a C3 targeting program, in partnership with Mallinckrodt Pharmaceuticals to reduce the expression of the C3 protein for the treatment of complement pathway-mediated diseases.  Silence maintains ongoing research and collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/